Early Statin Use Linked to Lower Dementia Risk

Starting statins soon after being diagnosed with type 2 diabetes has been linked to a 15% lower relative risk of developing dementia over 10 years, according to a large nationwide study.

Researchers examined health records from 132,585 people in Denmark who developed type 2 diabetes between 2006 and 2019 and had not previously taken statins.

Participants were divided according to when they started statin treatment.

Researchers classified those who began taking statins within one year of their diabetes diagnosis as early users, while those who started between one and five years later were classified as late users. They were compared with people who did not begin statins within five years.

The findings were striking.

Early statin treatment was associated with a 15% lower relative risk of dementia over 10 years compared with no statin initiation, while starting treatment later was associated with a 10% lower relative risk.

The research adds to growing interest in the relationship between cardiovascular health and brain health.

However, scientists stress that this was an observational study. It cannot establish that statins themselves caused the reduction in dementia risk.

How Big Was the Study?

The scale of the research is one of its strengths.

Scientists used Denmark’s nationwide health registers to identify 132,585 statin-naive people who developed type 2 diabetes between 2006 and 2019.

Participants were followed until they developed dementia, died, emigrated or reached the end of the study period on December 31, 2021.

The median follow-up was 7.1 years.

During that period, 3,592 people — around 2.7% of participants — developed dementia.

Researchers then estimated the participants’ dementia risk over a 10-year period according to when statin therapy began.

The estimated 10-year dementia risk was:

• 3.9% among those who did not initiate statins within five years.
• 3.5% among people who started statins between one and five years after diagnosis.
• 3.3% among those who started within the first year.

That final figure translates into a 15% relative reduction compared with the group that did not start statin treatment.

Relative Risk and Absolute Risk Are Different

The phrase “15% lower dementia risk” can sound larger than the underlying absolute difference, so understanding the numbers is important.

The estimated 10-year dementia risk declined from 3.9% without statin initiation to 3.3% with early initiation.

That represents an absolute difference of about 0.59 percentage points.

In simple terms, that is approximately six fewer dementia cases for every 1,000 people over the period examined.

The 15% figure describes the relative difference between the groups, rather than meaning that 15 out of every 100 people taking statins avoided dementia.

Both measurements are useful, but they describe the findings differently.

Why Were People With Type 2 Diabetes Studied?

People with type 2 diabetes are particularly important when researchers investigate dementia prevention.

Diabetes affects blood vessels throughout the body, including those supplying the brain.

Over time, high blood sugar, high blood pressure and abnormal cholesterol levels can contribute to cardiovascular and vascular damage.

People with diabetes also have an elevated risk of cardiovascular disease.

Because vascular health and brain health are closely connected, researchers have become increasingly interested in whether aggressively managing cardiovascular risk factors could also reduce the likelihood of dementia.

That is where statins become particularly interesting.

What Are Statins?

Statins are medications primarily used to lower cholesterol.

They reduce the production of cholesterol in the liver and are particularly effective at lowering low-density lipoprotein cholesterol, commonly known as LDL or “bad” cholesterol.

High LDL levels can contribute to fatty deposits accumulating inside arteries.

Over time, these deposits can restrict blood flow and increase the risk of heart attacks and strokes.

Statins are therefore commonly prescribed to people considered at increased cardiovascular risk, including many people with diabetes.

The drugs are already well established for preventing cardiovascular disease in appropriate patients.

The question raised by the latest research is whether earlier treatment might also have long-term implications for brain health.

Why Could Lower Cholesterol Protect the Brain?

Scientists have several possible explanations.

The brain depends on a healthy supply of blood and oxygen.

Damage to blood vessels can contribute to strokes and smaller vascular injuries that may gradually affect cognitive function.

Lowering LDL cholesterol reduces cardiovascular risk and could therefore indirectly protect the brain by maintaining healthier blood vessels.

Researchers are also investigating connections between cholesterol metabolism, inflammation and neurodegenerative processes.

But the exact biological relationship between statins and dementia remains uncertain.

The Danish study was designed to examine the association between the timing of statin treatment and dementia risk rather than determine precisely how statins might produce a protective effect.

Mechanisms of Vascular-Driven Brain Health

Starting Earlier Was Associated With the Biggest Difference

Timing was one of the most interesting aspects of the study.

People beginning statin treatment within one year of their type 2 diabetes diagnosis had the lowest estimated dementia risk.

Those starting between one and five years later also had a lower risk than people who did not start treatment, but the association was smaller.

Early initiation was associated with a 15% lower relative risk, compared with 10% for later initiation.

This stepwise pattern raises the possibility that controlling cardiovascular risk factors earlier could provide greater long-term benefits.

Researchers found broadly similar patterns in men and women.

Does This Prove Statins Prevent Dementia?

No.

This is probably the most important limitation to understand.

The study was observational, not a randomised clinical trial.

Researchers used sophisticated statistical techniques designed to emulate some features of a randomised trial, but participants were not randomly assigned to take or avoid statins.

That means other differences between people who received early treatment and those who did not could potentially have influenced the results.

For example, patients beginning treatment early may differ in their healthcare engagement, medical history or other behaviours.

Researchers attempted to account for potential biases, but observational research cannot eliminate them.

The authors therefore concluded that trial evidence is needed to confirm the findings.

Should People Start Statins to Prevent Dementia?

The study should not be interpreted as a recommendation for everyone to start taking statins specifically to prevent dementia.

Statins are prescription medicines, and whether someone should take them depends on their individual cardiovascular risk, cholesterol levels, medical history and other factors.

The established reason for prescribing statins remains the prevention of cardiovascular disease in people for whom treatment is appropriate.

The dementia findings provide an intriguing additional possibility, but they are not yet proof of a dementia-prevention treatment.

People should therefore discuss statin treatment with their doctor or another qualified healthcare professional rather than starting, stopping or changing medication based on this study alone.

What About Concerns That Statins Harm Memory?

Statins and cognitive health have generated debate for years.

Some people have worried that cholesterol-lowering drugs might negatively affect memory or increase dementia risk.

Scientific evidence has not established that statins cause dementia.

Research examining the issue has produced varying results depending on study design and population, and scientists continue to investigate the relationship.

The new Danish findings add evidence suggesting that statin treatment may instead be associated with lower dementia risk in a specific high-risk population — people developing type 2 diabetes.

But that does not mean every person taking a statin receives the same neurological benefit.

Why Cardiovascular Health Matters for Dementia

The research also highlights a broader development in dementia science.

Scientists increasingly recognise that dementia prevention cannot be separated from overall health.

Blood pressure, diabetes, cholesterol, smoking, physical inactivity and obesity can influence cardiovascular health, and several of these factors have also been associated with dementia risk.

Protecting blood vessels throughout adulthood may therefore help protect the brain later in life.

This does not mean dementia can always be prevented.

Age, genetics, and biological processes that are beyond an individual’s control remain important.

But identifying modifiable risk factors provides researchers potential opportunities to delay or reduce some cases.

Study Presented at ESC Congress 2026

The research was presented at ESC Congress 2026 and published in The Lancet Regional Health – Europe.

Researchers from Denmark used national health data covering more than a decade.

The study was funded by the Danish Cardiovascular Academy and the Danish Heart Foundation.

Its lead researchers emphasised that statins are already known to protect against cardiovascular disease and suggested that the dementia association provides another reason to investigate the benefits of timely cholesterol management in people with type 2 diabetes.

Crucially, they also called for randomised trial evidence to establish whether the association is genuinely causal.

Could Future Research Change Dementia Prevention?

Potentially.

If future randomised trials confirm that early cholesterol-lowering treatment directly reduces dementia risk, the findings could have important implications.

Millions of people worldwide live with type 2 diabetes.

Even a relatively modest reduction in dementia risk could therefore translate into a meaningful number of cases at the population level.

Researchers will need to determine whether the apparent protection comes directly from statins, from lower LDL cholesterol, from improved vascular health or from a combination of mechanisms.

They will also need to establish whether similar effects occur among people without diabetes.

Until then, the findings should be regarded as promising evidence rather than definitive proof.

Conclusion

The finding that early statin use was linked to a 15% lower dementia risk provides another intriguing connection between cardiovascular health and the ageing brain.

In a nationwide study involving more than 132,000 people with newly diagnosed type 2 diabetes, starting statins within one year was associated with the lowest estimated dementia risk over the following decade.

The estimated 10-year risk was 3.3% among early statin users compared with 3.9% among those who did not initiate statins within five years.

Starting treatment later was also associated with lower risk, although the difference was smaller.

The results are encouraging, but they do not prove that statins prevent dementia.

For now, the strongest conclusion is that managing cardiovascular risk early — particularly in people with type 2 diabetes — may have benefits that extend beyond the heart.

Further randomised clinical trials will be needed to determine whether protecting cardiovascular health with statins can directly help protect the brain as well

Medical note: This article is for general information and does not replace individual medical advice.

Make sure our latest headlines always appear at the top of your Google searches by adding us as a favourite source. Click here to activate. Or add us as your preferred source to your Google Search settings

Scientists Discover Major Brain Changes Between 50 and 75

Scientists have identified significant brain changes between 50 and 75 that could help explain why the risk of Alzheimer’s disease and other forms of dementia rises as people grow older.

Researchers studying the human hippocampus — a brain region crucial for learning and memory — discovered substantial changes in the cells responsible for protecting and maintaining the brain.

One of the most striking findings was that microglia, specialised immune cells that act as the brain’s resident maintenance and defence system, declined.

Between approximately ages 50 and 75, researchers found that many microglia originating during embryonic development declined. Concurrently, there was an increase in the prominence of cells that exhibited molecular characteristics similar to those of immune cells found in the bloodstream.

These replacement cells displayed stronger inflammatory signatures.

Scientists believe this previously underappreciated transformation could provide an important clue to understanding why ageing makes the brain increasingly vulnerable to chronic inflammation and neurodegenerative disease.

However, the research does not mean that everyone between 50 and 75 will experience cognitive decline or develop dementia. Instead, it identifies biological changes that researchers can investigate further to understand age-related disease risk.

What Did Scientists Discover?

The research examined how gene regulation changes as the human brain ages.

Scientists used advanced single-cell techniques to analyse tissue from the hippocampus, which plays a central role in memory and learning.

Rather than simply examining whether particular genes were active or inactive, researchers also investigated the epigenome and the three-dimensional organisation of DNA within individual brain cells.

This gave us a much clearer picture of what happens inside cells as the brain gets older.

The results indicated that ageing involves more than gradual deterioration.

Some cell populations appear to undergo substantial biological transformations during midlife and later adulthood.

One of the clearest periods of change occurred between approximately 50 and 75 years of age.

The Hippocampus Is Central to the Discovery

The hippocampus is particularly important because of its role in forming and retrieving memories.

It is also a region affected by Alzheimer’s disease.

Scientists therefore have considerable interest in understanding how its cells change during normal ageing.

The researchers examined postmortem hippocampal tissue from 40 neurologically healthy adults ranging from 20 to 95 years old.

Using sophisticated techniques capable of examining individual cells, they created a detailed picture of how cellular identity and genome regulation differed across adulthood.

The study revealed that the ageing process affects several types of brain cells differently.

But the changes involving microglia were particularly striking.

What Are Microglia?

Microglia are essentially the brain’s resident immune cells.

They perform several essential jobs.

They monitor the brain for signs of injury or infection, remove cellular waste and help maintain the environment needed for neurones to function properly.

They can be thought of as part of the brain’s biological housekeeping system.

For many years, scientists generally believed that microglia established during early development could renew themselves and remain within the brain throughout a person’s life.

The new findings challenge that assumption.

Researchers observed a substantial decline in these longstanding microglia between approximately ages 50 and 75.

At the same time, another population of cells became more prominent.

These cells displayed molecular characteristics resembling immune cells originating outside the brain.

That discovery raises intriguing questions about how the brain’s immune system changes as humans age.

Older Brain Immune Cells Show More Inflammatory Characteristics

One of the most important aspects of the discovery concerns inflammation.

The cells becoming more prominent in older brains showed stronger inflammatory signatures.

Inflammation is a normal and essential component of the immune response.

Short-term inflammation helps the body respond to infection and injury.

Chronic inflammation, however, can become harmful.

Researchers have long investigated the relationship between persistent inflammation in the brain and conditions including Alzheimer’s disease.

The newly identified immune-cell transition could potentially be one mechanism contributing to increased inflammation during ageing.

Scientists still need considerably more research before establishing exactly what role these cells play in neurodegenerative disease.

The current study identifies an association and a biological pathway worth investigating; it does not demonstrate that this cellular shift directly causes Alzheimer’s disease.

Blood-Brain Barrier Also Appears to Change

Microglia were not the only cells affected.

Researchers also detected a substantial decline in cell populations involved in maintaining the blood-brain barrier.

The blood-brain barrier is one of the body’s most important protective systems.

It acts as a selective boundary between the bloodstream and brain tissue.

Its job is to allow necessary nutrients to reach the brain while helping prevent potentially harmful substances from entering.

A weakening of the cells supporting this barrier could potentially make the ageing brain more vulnerable to inflammation or other damaging processes.

That makes this part of the discovery particularly important for future research.

The Brain’s DNA Organisation Changes With Age

The research went even deeper than individual immune cells.

Scientists found widespread age-related changes in how DNA is organised inside brain cells.

Human DNA does not simply sit inside the nucleus as a straight strand.

It folds into an extraordinarily complex three-dimensional structure.

That organisation matters because the physical positioning of different DNA regions helps determine which genes can be activated in cells.

Researchers discovered age-related deterioration in aspects of this three-dimensional genome organisation.

They also found changes in epigenetic regulation — chemical mechanisms that influence whether genes are switched on or off without altering the underlying DNA sequence.

These findings suggest that brain ageing involves extensive changes in how cells manage their genetic instructions.

Why Ages 50 to 75 Appear Important

One of the most attention-grabbing findings is the timing.

The decline in the original microglial population occurred progressively between approximately 50 and 75.

That does not mean the brain suddenly transforms on someone’s 50th birthday and finishes changing at 75.

Biological ageing is far more complicated.

Different people age at different rates, and genetics, the environment, cardiovascular health, and many other factors influence brain health.

Instead, researchers identified this age range as a period during which a substantial cellular transition became apparent across the samples studied.

That makes midlife particularly interesting to scientists investigating dementia.

Many neurological diseases become clinically apparent later in life, but the biological processes contributing to them may begin years or even decades earlier.

Could This Help Explain Alzheimer’s Disease?

Age is the biggest known risk factor for dementia.

Yet scientists still do not thoroughly understand exactly why getting older makes the brain so much more vulnerable to neurodegenerative disease.

This research provides a potential piece of the answer.

If the brain’s long-established immune cells decline and are replaced by cells with stronger inflammatory characteristics, the brain’s ability to maintain a healthy environment could change.

Bing Ren, one of the study’s corresponding authors, explained that microglia are essential for maintaining brain homeostasis.

When their housekeeping functions fail, harmful material may accumulate and contribute to inflammatory processes associated with neurodegenerative disease.

The findings could therefore help researchers investigate how normal biological ageing creates conditions in which diseases such as Alzheimer’s are more likely to develop.

But researchers have not shown that this immune-cell transition inevitably leads to Alzheimer’s.

Most people experiencing normal brain ageing will not necessarily develop the disease.

Does This Mean Cognitive Decline Starts at 50?

No.

That is an important distinction.

The research identified cellular and genomic changes beginning around midlife. It did not establish that everyone experiences noticeable memory loss starting at age 50.

Brain ageing varies substantially between individuals.

Some people retain excellent cognitive abilities well into their 80s and beyond.

Scientists are increasingly studying these differences because understanding why some brains remain resilient could be just as important as understanding why others develop disease.

The new research should therefore be interpreted as a discovery about brain biology, not as a prediction of what will happen to an individual person’s memory.

Could Scientists Eventually Slow This Process?

That is one of the biggest questions raised by the discovery.

If researchers can determine precisely why the microglial population changes, they may eventually be able to investigate whether that transition can be modified.

For example, future studies could examine whether reducing harmful inflammatory activity or supporting healthy microglial function could protect the ageing brain.

Researchers could also investigate whether maintaining the blood-brain barrier helps reduce vulnerability to neurological disease.

But these possibilities remain areas for future research.

The study does not currently provide a new treatment or prove that the cellular transition can be prevented.

Why the Study Has Limitations

Although the findings are significant, there are important limitations.

The research examined brain tissue from 40 people.

That provided scientists with extraordinarily detailed information at the cellular level, but it remains a relatively small sample.

The tissue was also obtained after death.

Researchers were therefore comparing brain samples from people of different ages rather than repeatedly examining the same individuals as they aged from 20 through 95.

Future research involving larger and more diverse groups will be important.

Scientists will also need to determine exactly where the replacement immune-like cells originate and whether the same patterns occur throughout other areas of the brain.

What Can People Do to Protect Brain Health?

The study itself does not prescribe any treatment or lifestyle programme.

However, existing evidence indicates that protecting cardiovascular and overall health during midlife is also important for long-term brain health.

Factors such as high blood pressure, diabetes and smoking are associated with dementia risk, while regular physical activity, adequate sleep, social engagement and management of hearing problems are among the areas researchers continue to study for maintaining cognitive health.

No lifestyle can guarantee that someone will avoid dementia.

But midlife is increasingly viewed as an important period for addressing modifiable health risks.

The new cellular research adds another reason scientists are paying particularly close attention to what happens inside the brain during these decades.

A New Window Into Human Brain Ageing

Perhaps the biggest importance of the study is the level of detail scientists can now achieve.

Older research often examined entire pieces of brain tissue.

Modern single-cell technology allows researchers to study thousands of individual cells and identify changes that might previously have been hidden.

Scientists can examine which genes are active, how DNA is chemically regulated and even how chromosomes are physically organised inside individual cells.

This technological progress is transforming how we study ageing.

Instead of simply observing that an older brain differs from a younger brain, researchers can begin identifying the specific cells and molecular processes responsible for those differences.

Conclusion

The discovery of major brain changes between 50 and 75 provides a fascinating new perspective on what happens inside the human brain as it ages.

Researchers found that longstanding microglia in the hippocampus decline substantially during this period, while cells with more inflammatory characteristics become increasingly prominent.

They also identified reductions in cells that support the blood-brain barrier, as well as extensive changes in gene regulation and the three-dimensional organisation of the genome.

These findings could eventually help scientists understand why ageing dramatically increases vulnerability to Alzheimer’s disease and other neurodegenerative conditions.

But the research should not be interpreted as evidence that cognitive decline inevitably begins at 50.

Instead, scientists have uncovered a previously underappreciated biological transition that may help explain how the ageing brain changes — and potentially point to new areas for preventing or treating age-related neurological disease in the future.